These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26022732)

  • 21. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
    Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.
    Liu Y; Xu L; Hennig AK; Kovacs A; Fu A; Chung S; Lee D; Wang B; Herati RS; Mosinger Ogilvie J; Cai SR; Parker Ponder K
    Mol Ther; 2005 Jan; 11(1):35-47. PubMed ID: 15585404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression.
    Meertens L; Zhao Y; Rosic-Kablar S; Li L; Chan K; Dobson H; Gartley C; Lutzko C; Hopwood J; Kohn D; Kruth S; Hough MR; Dubé ID
    Hum Gene Ther; 2002 Oct; 13(15):1809-20. PubMed ID: 12396614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucopolysaccharidoses type I gene therapy.
    Hurt SC; Dickson PI; Curiel DT
    J Inherit Metab Dis; 2021 Sep; 44(5):1088-1098. PubMed ID: 34189746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits.
    Baldo G; Wozniak DF; Ohlemiller KK; Zhang Y; Giugliani R; Ponder KP
    J Inherit Metab Dis; 2013 May; 36(3):499-512. PubMed ID: 22983812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
    Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
    Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzymatic correction and cross-correction of mucopolysaccharidosis type I fibroblasts by adeno-associated virus-mediated transduction of the alpha-L-iduronidase gene.
    Hartung SD; Reddy RG; Whitley CB; McIvor RS
    Hum Gene Ther; 1999 Sep; 10(13):2163-72. PubMed ID: 10498248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.
    Dai M; Han J; El-Amouri SS; Brady RO; Pan D
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2680-5. PubMed ID: 24550296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.
    Wolf DA; Hanson LR; Aronovich EL; Nan Z; Low WC; Frey WH; McIvor RS
    Mol Genet Metab; 2012 May; 106(1):131-4. PubMed ID: 22420937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
    Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
    J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors.
    Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L
    Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.
    Wolf DA; Lenander AW; Nan Z; Belur LR; Whitley CB; Gupta P; Low WC; McIvor RS
    Neurobiol Dis; 2011 Jul; 43(1):123-33. PubMed ID: 21397026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction.
    Podetz-Pedersen KM; Laoharawee K; Singh S; Nguyen TT; Smith MC; Temme A; Kozarsky K; McIvor RS; Belur LR
    Hum Gene Ther; 2023 Jan; 34(1-2):8-18. PubMed ID: 36541357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.
    Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL
    Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals.
    Hinderer C; Bell P; Katz N; Vite CH; Louboutin JP; Bote E; Yu H; Zhu Y; Casal ML; Bagel J; O'Donnell P; Wang P; Haskins ME; Goode T; Wilson JM
    Hum Gene Ther; 2018 Jan; 29(1):15-24. PubMed ID: 28806897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies.
    Visigalli I; Delai S; Ferro F; Cecere F; Vezzoli M; Sanvito F; Chanut F; Benedicenti F; Spinozzi G; Wynn R; Calabria A; Naldini L; Montini E; Cristofori P; Biffi A
    Hum Gene Ther; 2016 Oct; 27(10):813-829. PubMed ID: 27431943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
    Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
    Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
    Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
    Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.